Carmell Therapeutics Corporation (CTCX) - Total Liabilities
Based on the latest financial reports, Carmell Therapeutics Corporation (CTCX) has total liabilities worth $7.14 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Carmell Therapeutics Corporation growing its equity to track the company's year-over-year net asset growth rate.
Carmell Therapeutics Corporation - Total Liabilities Trend (2021–2024)
This chart illustrates how Carmell Therapeutics Corporation's total liabilities have evolved over time, based on quarterly financial data.
Carmell Therapeutics Corporation Competitors by Total Liabilities
The table below lists competitors of Carmell Therapeutics Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
USA | $793.06K |
|
Sentral Mitra Informatika Tbk PT
JK:LUCK
|
Indonesia | Rp22.81 Billion |
|
Jain Irrigation Systems Limited
NSE:JISLDVREQS
|
India | Rs61.58 Billion |
|
Picton Property Income Ltd
LSE:PCTN
|
UK | GBX229.33 Million |
|
Biomerica Inc
NASDAQ:BMRA
|
USA | $1.56 Million |
|
PLENUM AG NA O.N.
F:PLEK
|
Germany | €8.32 Million |
|
Sentage Holdings Inc
NASDAQ:SNTG
|
USA | $2.00 Million |
|
Alpha Compute Corp
NASDAQ:ALP
|
USA | $21.70 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Carmell Therapeutics Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Carmell Therapeutics Corporation (CTCX) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Carmell Therapeutics Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Carmell Therapeutics Corporation (2021–2024)
The table below shows the annual total liabilities of Carmell Therapeutics Corporation from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.19 Million | -84.22% |
| 2023-12-31 | $39.20 Million | -0.86% |
| 2022-12-31 | $39.54 Million | +27.00% |
| 2021-12-31 | $31.13 Million | -- |
About Carmell Therapeutics Corporation
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on … Read more